» Articles » PMID: 12441828

Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy

Overview
Journal Clin J Pain
Specialties Neurology
Psychiatry
Date 2002 Nov 21
PMID 12441828
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This article reviews the prevalence, risk factors, natural history, and impact on quality of life of painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN).

Discussion: Diabetes mellitus afflicts more than 14 million persons in the U.S. An estimated 20% to 24% of these persons experience PDN. Data on risk factors for PDN are limited, but duration of diabetes mellitus and poor glycemic control are probably important factors. Painful diabetic neuropathy may interfere with general activity, mood, mobility, work, social relations, sleep, leisure activities, and enjoyment of life. Herpes zoster strikes an estimated 800,000 persons each year in the U.S., most of whom are elderly or immunosuppressed. Using pain at 3 months after rash onset as a definition of PHN, between 25% and 50% of adults older than 50 years develop PHN, depending on early antiviral therapy for herpes zoster. Increasing age, greater pain and rash severity, greater degree of sensory impairment, and psychological distress are risk factors for PHN. Postherpetic neuralgia may cause fatigue, insomnia, depression, anxiety, interference with social roles and leisure activity, and impaired basic and instrumental activities of daily living.

Conclusions: Both conditions are common complications of their underlying disorders and can profoundly diminish the quality of life of affected persons.

Citing Articles

Efficacy and Safety of Ultrasound-Guided Pulsed Radiofrequency Therapy of Stellate Ganglion on Refractory Painful Diabetic Peripheral Neuropathy.

Wang J, Xu W, Wang Q, Yang P, Kan Y, Huang C J Pain Res. 2024; 17:4521-4531.

PMID: 39737247 PMC: 11683198. DOI: 10.2147/JPR.S497061.


Effect of topical on painful diabetic neuropathy: a double-blind randomized-controlled trial.

Jatuten N, Piyakunmala P, Budkaew J, Chumworathayi B F1000Res. 2024; 12:334.

PMID: 39220605 PMC: 11364968. DOI: 10.12688/f1000research.131344.2.


Preclinical Evaluation of Sigma 1 Receptor Antagonists as a Novel Treatment for Painful Diabetic Neuropathy.

Peng Y, Zhang A, Wei L, Welsh W ACS Pharmacol Transl Sci. 2024; 7(8):2358-2368.

PMID: 39144554 PMC: 11320727. DOI: 10.1021/acsptsci.4c00186.


Efficacy and safety of acupuncture for painful diabetic neuropathy: a systematic review and meta-analysis.

Liu J, Lin Y, Huang Y, Yang Q, Li X, Ye Y Front Neurol. 2024; 15:1402458.

PMID: 38903165 PMC: 11188462. DOI: 10.3389/fneur.2024.1402458.


Expert Consensus on Ion Channel Drugs for Chronic Pain Treatment in China.

Ma K, Cheng Z, Jiang H, Lin Z, Liu C, Liu X J Pain Res. 2024; 17:953-963.

PMID: 38476873 PMC: 10929561. DOI: 10.2147/JPR.S445171.